Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-06
2011-11-15
Spivack, Phyllis G. (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263200, C514S263220, C514S263300
Reexamination Certificate
active
08058281
ABSTRACT:
The present invention is directed to a method of treating systemic lupus erythematosus comprising administering a compound of formula (I)whereinR1 is selected from the group consisting of CF3, a C1-C5alkyl, and (CH2)nR4, wherein n is between 0 and 4;R2 is selected from the group consisting of (CH2)mR4 and (CH2)mAr, wherein m is between 0 and 5;R3 is selected from the group consisting of hydrogen and methyl;R4 is selected from the group consisting of phenyl, OH, a C1-C3alkoxy, a C1-C3dialkylamino, piperidino, and N-methylpiperazino;Ar represents wherein X is selected from the group consisting of F, C1, a C1-C3alkoxy, and CF3. The compounds can be used in combination with a second compound used in the treatment of systemic lupus erythematosus.
REFERENCES:
patent: 6716987 (2004-04-01), Ohshima et al.
patent: 2003/0104974 (2003-06-01), Pitts et al.
patent: 1043021 (2000-10-01), None
patent: 2004014913 (2004-02-01), None
Eisenberg, R., Journal Autoimmunity., 32(3-4), (May-Jun. 2009), pp. 223-230 (Abstract).
Boichot Elisabeth et al:“Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine” Journal of Pharmacology and Experimental Therapeutics, vol. 292, No. 2, (2000), pp. 641-653.
International Search Report, PCT/EP2007/052084.
Rahman et al., N. Engi. J Med., 358: 929-939, (2008).
Muller et al., Arthritis Rheum., 58(12): 3873-3883, (2008).
Sahebari et al., Arch. Iran Med.,13(2): 135-142, (2010).
Furrie et alt., Arthritis Res Ther., 10(5): R109, (2008).
Bourguignon Jean-Jaques
Lugnier Claire Renée Jeanne
Monneaux Fanny Sylvie Michele
Muller Sylviane Paule Ghislaine
Centre National de la Recherche Scientifique "CNRS"
Lerner David Littenberg Krumholz & Mentlik LLP
Spivack Phyllis G.
LandOfFree
Use of adenine-derived compounds for the treatment of lupus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of adenine-derived compounds for the treatment of lupus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of adenine-derived compounds for the treatment of lupus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4254588